New information has come to light regarding the FDA-recalled 'microdosing' candy that was recently on sale locally. According to a recent FDA report, images of Diamond Shruumz-Brand Microdosing Chocolate Bars, Cones, & Gummies have surfaced, shedding light on the contents of the products.
FDA Evidence Uncovered
Following a recall in June of Diamond Shruumz-brand products, the U.S. Food and Drug Administration has revealed that the 'microdosing' candies were found to contain a Schedule I-controlled substance, a prescription drug, or a mixture of compounds. This revelation has sparked concern among consumers and health officials alike.
Misleading Marketing Claims
Diamond Shruumz had promoted on its website that their candies offered a journey of creativity and peace of mind, with no psilocybin or scheduled drugs included. However, the recent FDA findings have contradicted these claims, raising questions about the accuracy of the company's marketing.
Potential Health Risks
With the discovery of potentially harmful substances in the 'microdosing' candies, consumers are being urged to be cautious and avoid consuming these products. The FDA is working diligently to investigate the situation further and ensure the safety of the public.
Conclusion
The emergence of new evidence regarding the Diamond Shruumz 'microdosing' candies highlights the importance of transparency and regulation in the food and drug industry. Consumers are advised to stay informed and vigilant when purchasing products, especially those making health-related claims.